After Inotuzumab: New Platforms Promise More Than Better Antibody-Drug Conjugates
Versatile next-generation antibody-drug conjugate platforms promise to turn out ADCs with better specificity and safety than current technologies, as well as combination therapeutics like bi-specific antibodies, but old-school molecules continue to move through clinical trials and gain approval.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
After almost two decades at Millennium/Takeda, Anna Protopapas moves to tiny Mersana Therapeutics, which aims to power up oncology with its Fleximer drug conjugate platform.
Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen